• Small Molecules
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

CAR-T

CAR T-cell therapies combine cellular therapy, gene therapy and immune therapy to use a patient’s own T-cells to fight cancers. It is this potential for harnessing our immune systems to fight cancer that makes CAR T-cell therapies so revolutionary and earns them the name, “living drugs”.

Syngene is contributing to this revolutionary field by helping our clients evaluate their novel medicines/molecules for their mode of action, in vivo functional efficacy and other vital characteristics.  Our end-to-end in vitro and in vivo immuno-oncology assessment platform allows the fast and accurate validation of treatment approaches.


Our capabilities that support CAR T-Cell research

  • Design of CAR constructs
  • CRISP-R gene editing
  • Primary T-cell assays
    • Human PBMCs isolation, sorting
    • Cytotox assay with co-cultured cancer cells
    • Proliferation
    • Cytokine profile
  • Virus generation for CAR delivery
    • Lentivirus packaging
    • Transduction efficiency
  • Efficacy studies in syngeneic models
  • Ex-vivo immuno-phenotyping of TILs
  • PDX and humanized mouse models
  • Pre-clinical evaluation
    • In vivo proliferation of effector cells: CAR expression and CFSE assay
    • Xenograft tumor growth inhibition (NOG-SCID mice)
    • Survival as endpoint
    • Whole animal imaging – Biodistribution
  • Biorepositories
    • Collaboration with multiple local and national medical centers for healthy and patients’ samples (blood, tissues)
    • Currently banking >200 healthy donor PBMC ready to use

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details